Search Within

Melanoma Disease Management Team

  1. "Journal for ImmunoTherapy of Cancer"
Formats
  1. Meeting Abstract (33)
  2. Journal Article (27)
  3. Guidelines (3)
  4. Editorial (1)
Groups
  1. Department of Medicine (60)
  2. Solid Tumor Oncology Division (60)
  3. Melanoma and Immunotherapeutics Service (56)
  4. GSK Faculty (29)
  5. Hematologic Malignancies, Division of (26)
  6. Sloan Kettering Institute Postdocs (14)

More Groups

People
  1. Michael Postow (34)
  2. Jedd Wolchok (25)
  3. Alexander Shoushtari (17)
  4. Margaret Callahan (8)
  5. Roberta Zappasodi (7)
  6. Taha Merghoub (7)

More People

Years
  1. 2024 (3)
  2. 2023 (4)
  3. 2022 (10)
  4. 2021 (8)
  5. 2020 (8)
  6. 2019 (5)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (64)
Publishers
  1. Biomed Central Ltd (64)

Results (64)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
    Journal Article

    Kudelka, M. R.; Richards, A. L.; Friedlander, P.; Wolchok, J. D.; Moy, A. P.; Shoushtari, A. N.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Open-capsule budesonide for the treatment of immune-related enteritis from checkpoint inhibitors
    Journal Article

    Magahis, P. T.; Corso, T.; Livingstone, P.; Tom, E.; Srivastava, A.; Postow, M.; Faleck, D.
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
    Journal Article

    Sacco, J. J.; Carvajal, R. D.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A.; Hernandez-Aya, L.; Nathan, P.; Hamid, O.; Piulats, J. M.; more...
    Journal for ImmunoTherapy of Cancer (2024)

    Fulltext@MSK | Save
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
    Guidelines

    Pavlick, A. C.; Ariyan, C. E.; Buchbinder, E. I.; Davar, D.; Gibney, G. T.; Hamid, O.; Hieken, T. J.; Izar, B.; Johnson, D. B.; Kulkarni, R. P.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
    Journal Article

    Badran, Y. R.; Zou, F.; Durbin, S. M.; Dutra, B. E.; Abu-Sbeih, H.; Thomas, A. S.; Altan, M.; Thompson, J. A.; Qiao, W.; Leet, D. E.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Management of immune-related cutaneous adverse events with dupilumab
    Journal Article

    Kuo, A. M. S.; Gu, S.; Stoll, J.; Moy, A. P.; Dusza, S. W.; Gordon, A.; Haliasos, E. C.; Janjigian, Y.; Kraehenbuehl, L.; Quigley, E. A.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: A phase 1 study
    Journal Article

    Hamid, O.; Hassel, J. C.; Shoushtari, A. N.; Meier, F.; Bauer, T. M.; Salama, A. K. S.; Kirkwood, J. M.; Ascierto, P. A.; Lorigan, P. C.; Mauch, C.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Assessing the correlation between CD8 cell PET imaging with 89-ZR-crefmirlimab berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy
    Meeting Abstract

    Postow, M.; Mauguen, A.; Farwell, M.; Gordon, M.; Hays, D.; Wong, J.; Pal, S.; Chen, D.; Ulaner, G.; McConathy, J.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Comparative safety and effectiveness of IL6R inhibitors, TNF inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis
    Meeting Abstract

    Bass, A.; Abdel-Wahab, N.; Sparks, J.; Reid, P.; Calabrese, C.; Jannat-Khah, D.; Rajesh, D.; Ghosh, N.; Mushtak, K.; Al Haj, F.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Repeat dosing of oncolytic adenovirus ONCOS-102 is associated with enhanced and persistent immune responses and improved systemic activity in anti-PD-1 resistant/refractory (R/R) melanoma
    Meeting Abstract

    Shoushtari, A.; Ottesen, L.; Levitsky, V.; Hansen, T. B.; Hornyak, T.; Olszanski, A.; Nyakas, M.; Wolchok, J.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save